Halozyme Therapeutics, Inc. (HALO) Wednesday said that Bristol-Myers Squibb Company (BMY) received approval from the European Commission (EC) for a new subcutaneous (SC) formulation of Opdivo developed with Halozyme's proprietary drug delivery technology ENHANZE, for use across various adult solid tumors.
The approval was supported by positive results from the Phase 3 CheckMate -67T study.
The FDA approved Opdivo SC, marketed under the brand name Opdivo Qvantig, in December last year.
"This approval is just one of the 11 growth catalysts for our commercialized SC products expected this year," said Helen Torley, president and chief executive officer of Halozyme.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.